MEDROXYPROGESTERONE ACETATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1959)
Entry Type: Small molecule
Molecule Category: Parent
UNII: C2QI4IOI2G
Parent Compound: MEDROXYPROGESTERONE

Structure
InChI Key PSGAAPLEWMOORI-PEINSRQWSA-N
Smile CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChI
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H34O4
Molecular Weight 386.53
AlogP 4.66
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 2.0
Polar Surface Area 60.44
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Progesterone receptor agonist DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Oxidoreductase
- 3981-4100 - - -
Enzyme
- 300-2512 - - -
Secreted protein
- - 631 - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 1
924 924-924 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group A Nuclear hormone receptor subfamily 3 group A member 2
924 924-924 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
10-10 10-10 - 13-13 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 2
- 1197-1197 - - -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
0-1 11-11 - 0-1 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 4
6-6 36-794 - 3-3 -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 104
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 15700 - - -
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
- 22500 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Hemorrhage 4 D006470 ClinicalTrials
Carcinoma, Renal Cell 4 D002292 ClinicalTrials
Infertility 3 D007246 ClinicalTrials
Hypertension 3 D006973 ClinicalTrials
Myocardial Ischemia 3 D017202 ClinicalTrials
Hypercholesterolemia 3 D006937 ClinicalTrials
Hot Flashes 3 D019584 ClinicalTrials
Thrombosis 3 D013927 ClinicalTrials
Menopause 3 D008593 ClinicalTrials
Kidney Neoplasms 3 D007680 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials
Lupus Erythematosus, Systemic 3 D008180 ClinicalTrials
Heart Diseases 3 D006331 ClinicalTrials
Osteoporosis 3 D010024 ClinicalTrials
Menorrhagia 3 D008595 ClinicalTrials
Turner Syndrome 3 D014424 ClinicalTrials
Diabetes Mellitus 3 D003920 ClinicalTrials
Alzheimer Disease 2 D000544 ClinicalTrials
Sleep Apnea Syndromes 2 D012891 ClinicalTrials
Endometrial Hyperplasia 2 D004714 ClinicalTrials
HIV Infections 2 D015658 ClinicalTrials
Primary Ovarian Insufficiency 2 D016649 ClinicalTrials
HIV Infections 2 D015658 ClinicalTrials
Pain 2 D010146 ClinicalTrials
Pregnancy 1 D011247 ClinicalTrials

Related Entries

Scaffolds

Parent
Mixture
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.18
Reproductive system and breast disorders
11.31
Psychiatric disorders
8.62
Nervous system disorders
8.1
Injury, poisoning and procedural complications
7.86
Musculoskeletal and connective tissue disorders
6.74
Vascular disorders
5.54
Skin and subcutaneous tissue disorders
5.48
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
5.08
Gastrointestinal disorders
4.21
Investigations
4.1
Metabolism and nutrition disorders
3.23
Cardiac disorders
3.02
Immune system disorders
2.69
Respiratory, thoracic and mediastinal disorders
2.24
Pregnancy, puerperium and perinatal conditions
2.15

Cross References

Resources Reference
CAS NUMBER 71-58-9
ChEBI 6716
ChEMBL CHEMBL717
DrugBank DB00603
DrugCentral 1659
EPA CompTox DTXSID0025527
FDA SRS C2QI4IOI2G
KEGG C08150
PubChem 6279
SureChEMBL SCHEMBL4276
ZINC ZINC000005029557
CONTENTS